0
0
The Indian government has firmly opposed a public interest litigation (PIL) in the Delhi High Court seeking to classify air purifiers as “medical devices” and slash their GST from 18% to 5%, arguing it lacks genuine public interest and could disrupt supply chains. Filed by advocate Kapil Madan, the petition highlights Delhi-NCR’s worsening air pollution as an “extreme emergency,” claiming air purifiers with HEPA filters prevent respiratory diseases by reducing PM2.5 and PM10 exposure. On January 9, 2026, the court granted the petitioner time to respond and scheduled the next hearing for March 19, amid ongoing debates on clean air access.
Case Background
The PIL invokes a February 2020 notification under the Drugs and Cosmetics Act, 1940, which broadened “medical device” definitions to include items preventing disease through physical means, positioning air purifiers as essential for respiratory health in polluted regions. Currently, air purifiers fall under HSN 8421 with 18% GST, while many medical devices attract 5% under HSN 9018-9022, following GST Council rationalizations. The court earlier urged the GST Council to consider rate cuts, noting poor AQI levels, but the Centre stressed judicial intervention violates separation of powers and Article 279A’s cooperative federalism.
Delhi-NCR’s air crisis fuels the urgency: over 204,758 respiratory illness cases reported in government hospitals from 2022-2024, with 30,420 admissions, linked to PM2.5 triggering asthma, COPD, and cardiovascular issues. WHO data shows Delhi’s PM10 at 198 μg/m³, exceeding limits by 10 times, with vehicular emissions and industry as key culprits.
Government’s Stance
In its affidavit, the Centre called the PIL “colourable and motivated,” suggesting reclassification under Medical Devices Rules, 2017, would impose strict licensing, import, and distribution regulations, potentially creating monopolies for licensed entities and reducing market supply. Additional Solicitor General N. Venkataraman argued GST matters rest exclusively with the GST Council, not courts, as rate changes require Fitment Committee scrutiny and state consensus. The government noted parliamentary committees are already reviewing purifier taxes, dismissing luxury labeling since 18% is below the 28% highest slab.
Classifying purifiers as medical devices would not automatically lower GST, the Centre clarified, as taxation follows separate HSN frameworks.
Health Impacts Driving Demand
Delhi’s pollution exacts a heavy toll: studies link elevated PM2.5 to increased natural-cause mortality, emergency asthma visits, and coronary events. A randomized trial found air purifiers cut indoor PM2.5 by 57% (from 96.2 to 41.3 μg/m³), reducing inflammatory biomarkers like MCP-1 by 17.5% and IL-1β by 68.1%. Another review showed 22.6-92% PM2.5 reductions, benefiting allergic rhinitis patients and lowering blood pressure in seniors.
India’s air purifier market, valued at $63 million in 2025, may hit $120 million by 2032, driven by urban smog, with 2.5 lakh units sold in 2024. Pulmonologist Dr. Vikas Mittal notes purifiers aid symptom relief, though evidence varies. Dr. Sharad Joshi recommends them alongside masks and ventilation for vulnerable groups during high AQI.
Expert Perspectives
Medical device expert Rajiv Nath, forum coordinator at AiMeD, argues air purifiers fail CDSCO criteria for diagnosis, treatment, or prevention, unlike N95 masks post-COVID. “They reduce ambient particulates but do not directly impact the body,” Nath stated, warning reclassification could stifle innovation without proven clinical benefits.
Conversely, Dr. Puneet Gupta, Head of Pulmonology at Yatharth Super Speciality Hospital, highlights purifiers’ role in curbing shortness of breath and COPD flares from Delhi’s ozone and NO2 mix. “Even short visits trigger inflammation; purifiers offer indoor refuge,” he said. Dr. Manchanda adds they alleviate fatigue and irritation for all, not just the ill.
GST Council sources indicate potential standalone rate cuts to 5% without reclassification, possibly discussed soon, enhancing affordability by 10-15%.
Public Health Implications
Reclassification could limit access in a constrained market, per the Centre, but lower GST alone might boost adoption amid 2 lakh+ annual respiratory cases. For consumers, especially in Punjab and northern India like Kharar, where stubble burning worsens winter AQI, affordable purifiers mean practical protection: select HEPA models for 300-500 sq ft rooms, maintain filters quarterly, and pair with open windows on good air days.
Limitations include uneven efficacy—purifiers handle particulates but not gases like NO2—and high upfront costs (₹10,000-30,000). No consensus exists on preventing diseases outright, and outdoor fixes like GRAP Stages remain vital. Balanced policy weighs health gains against regulatory burdens.
Regulatory and Future Outlook
Medical Devices Rules, 2017, classify by risk (A-D), requiring notified devices to meet quality standards, absent for purifiers. The PIL tests if pollution elevates them to “preventive” status under 2020 expansions. With GST Council eyeing cuts independently, judicial relief may prove unnecessary, prioritizing supply over stringent oversight.
As March hearings loom, the debate underscores India’s clean air challenge: 36% hypertension prevalence tied to particulates in Delhi studies. Stakeholders urge evidence-based access without market distortion.
References
-
Economic Times Health. “No genuine public interest in plea to classify air purifiers as medical devices: Centre to Delhi HC.” January 10, 2026. https://health.economictimes.indiatimes.com/news/policy/no-genuine-public-interest-in-plea-to-classify-air-purifiers-as-medical-devices-centre-to-delhi-hc/126446355
Medical Disclaimer: This article is for informational purposes only and should not be considered medical advice. Always consult with qualified healthcare professionals before making any health-related decisions or changes to your treatment plan. The information presented here is based on current research and expert opinions, which may evolve as new evidence emerges.
